Skip to main content
SpringerLink
Log in

Update Kardiologie 2020

Cardiology update 2020

  • Leitthema
  • Published:
Der Diabetologe Aims and scope

Zusammenfassung

Das hohe kardiovaskuläre Risiko von Patienten mit Diabetes verlangt nach einer optimalen Kontrolle der entsprechenden Risikofaktoren. Im letzten Jahr erschienen verschiedene Studien und Leitlinien, die dies untermauern und hier vorgestellt und diskutiert werden. Im Fokus stehen die Lipidtherapie, die Behandlung des Typ-2-Diabetes, die Antikoagulation und Thrombozytenaggregationshemmung sowie auch die Revaskularisation und Behandlung bei Herzinsuffizienz.

Abstract

The cardiovascular risk of patients with type 2 diabetes requires efficient therapy of all risk factors. A variety of new studies and guidelines have been published over the last year which will be presented and discussed in this article. These include lipid, diabetes and anti-thrombotic therapy in addition to revascularization and heart failure treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Abbreviations

95 %-KI:

95 %-Konfidenzintervall

ACE:

Angiotensinkonversionsenzym

ACR:

Verhältnis Albumin zu Kreatinin („albumin to creatinine ratio“)

ASS:

Azetylsalizylsäure

BMI:

Body-Mass-Index

CHA2DS2-VASc:

C: Herzinsuffizienz, H: Hypertension, A2: Alter≥ 75 Jahre, D: Diabetes mellitus, S2: vorangegangener Schlaganfall/transitorische ischämische Attacke oder Thrombembolie, V: periphere arterielle Verschlusskrankheit, A: Alter 65–74 Jahre, Sc: weibliches Geschlecht

CRP:

C‑reaktives Protein

CT:

Computertomographie

CV:

Kardiovaskulär

DOAC:

Direkte orale Antikoagulanzien

DPP:

Dipeptidylpeptidase

EKG:

Elektrokardiographie

ESC:

„European Society of Cardiology“

FFR :

Fraktionelle Flussreserve

GFR:

Glomeruläre Filtrationsrate

GLP‑1:

„Glucagon-like peptide 1“

HAS-BLED :

H: Hypertonie, A: abnormale Nieren‑/Leberfunktion, S: Schlaganfall, B: Blutung, L: labile INR-Einstellung (INR: „international normalized ratio“), E: Alter, D: Drogen und Alkohol

HbA1c :

Glykohämoglobin Typ A1c

HDL:

„High density lipoprotein“

HDL‑C:

HDL-Cholesterin

HFrEF:

„Heart failure with reduced ejection fraction“

IL:

Interleukin

KHK:

Koronare Herzkrankheit

LDL:

„Low density lipoprotein“

LDL‑C:

LDL-Cholesterin

LVEF :

Linksventrikuläre Ejektionsfraktion

MACE:

„Major adverse cardiac events“

MRT:

Magnetresonanztomographie

NNT:

„Number needed to treat“

NOAC:

Nicht-Vitamin-K-antagonistische orale Antikoagulanzien

NT-proBNP:

„N-terminal pro b‑type natriuretic peptide“

NYHA :

„New York Heart Association“

OR:

„Odds ratio“

PCI:

Perkutane koronare Intervention

PCSK9 :

Proproteinkonvertase Subtilisin/Kexin Typ 9

RAAS:

Renin-Angiotensin-Aldosteron-System

SGLT‑2:

„Sodium dependent glucose transporter 2“

T1D:

Typ-1-Diabetes

T2D:

Typ-2-Diabetes

TIA:

Transitorische ischämische Attacke

UK:

„United Kingdom“

Literatur

  1. Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MS (2019) Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. https://doi.org/10.1001/jama.2019.14120

  2. Amarenco P, Kim JS, Labreuche J et al (2020) A comparison of two LDL cholesterol targets after Ischemic stroke. N Engl J Med 382(1):9

    Article  CAS  PubMed  Google Scholar 

  3. Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188

    Article  PubMed  Google Scholar 

  4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577–1589

    Article  CAS  PubMed  Google Scholar 

  5. Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Study Research G (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39(5):686–693

    Article  Google Scholar 

  6. Reaven PD, Emanuele NV, Wiitala WL et al (2019) Intensive glucose control in patients with type 2 diabetes—15-year follow-up. N Engl J Med 380(23):2215–2224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy. N Engl J Med 380(24):2295–2306

    Article  CAS  PubMed  Google Scholar 

  8. Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844

    Article  CAS  PubMed  Google Scholar 

  10. Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529

    Article  CAS  PubMed  Google Scholar 

  11. Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130

    Article  CAS  PubMed  Google Scholar 

  12. Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323

    Article  PubMed  Google Scholar 

  13. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865

    Article  Google Scholar 

  14. Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131

    Article  CAS  PubMed  Google Scholar 

  15. Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose Colchicine after myocardial infarction. N Engl J Med 381(26):2497–2505

    Article  CAS  PubMed  Google Scholar 

  16. Yasuda S, Kaikita K, Akao M et al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381(12):1103–1113

    Article  CAS  PubMed  Google Scholar 

  17. Matsumura-Nakano Y, Shizuta S, Komasa A et al (2019) Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary Stent implantation. Circulation 139(5):604–616

    Article  CAS  PubMed  Google Scholar 

  18. Knuuti J, Wijns W, Saraste A et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41(3):407–477

    Article  PubMed  Google Scholar 

  19. McMurray JJV, Docherty KF, Jhund PS (2020) Dapagliflozin in patients with heart failure and reduced ejection fraction. Reply. N Engl J Med 382(10):973

    PubMed  Google Scholar 

  20. Marx N (2020) Reduction of cardiovascular risk in patients with T2DM by GLP‑1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa174

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin (Med. Klinik I), Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland

    Michael Lehrke

Authors
  1. Michael Lehrke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Lehrke.

Ethics declarations

Interessenkonflikt

M. Lehrke weist auf folgende Beziehungen hin. Forschungsunterstützung für experimentelle und klinische Studien von Boehringer Ingelheim, Novo Nordisk und MSD; Beratertätigkeit für Boehringer Ingelheim, Sanofi-Aventis, MSD, AstraZeneca, Lilly, NovoNordisk, Amgen und Bayer. Vortragstätigkeit für Boehringer Ingelheim Sanofi-Aventis, MSD, AstraZeneca, Lilly, NovoNordisk and Bayer.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lehrke, M. Update Kardiologie 2020. Diabetologe 16, 461–469 (2020). https://doi.org/10.1007/s11428-020-00623-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-020-00623-w

Schlüsselwörter

Keywords

Search

Navigation